Volpara Health collaborates with Microsoft to accelerate the research and development of software that uses mammograms to identify potential cardiovascular issues
Retrieved on:
Thursday, August 4, 2022
FDA, Woman, Machine learning, Cardiovascular disease, Chief innovation officer, Microsoft Azure, Risk, Degenerative disease, Technology, Software, Highnam, BAC, Patent, Research, Software as a service, Microsoft, Patient, Company, List of life sciences, Radiology, Doctor of Philosophy, Artificial intelligence, Science, Volpara, Physician, Health, Disease, Adoption, Calcification, Medical imaging, Pharmaceutical industry, Azure, Group
SEATTLE, Aug. 4, 2022 /PRNewswire/ -- Volpara Health Technologies ("Volpara," "the Group," or "the Company"; ASX: VHT), a global health technology software leader providing an integrated platform for personalized breast care, today announced a new research and development agreement with Microsoft to accelerate the creation of a solution that detects and quantifies breast arterial calcifications (BAC).
Key Points:
- Integrating Microsoft Azure Machine Learning, part of the Azure AI platform, will help improve Volpara's BAC model and data processing.
- Microsoft SaaS and cloud products have played a fundamental role in supporting Volpara's development of the latest, FDA-cleared version of their core AI algorithm.
- For women, the BAC product would add a new dimension to their regular breast screenings, providing important information about their cardiovascular health.
- Though we are in the early stages of BAC product development, this collaboration will accelerate our efforts as we advance science together."